(VIANEWS) – Evercore Partners (EVR), Halozyme Therapeutics (HALO), First Hawaiian (FHB) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Evercore Partners (EVR)
30.8% sales growth and 17.78% return on equity
Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers strategic advisory services, such as mergers and acquisitions, strategic, defense, and shareholder advisory, special committee assignments, and transaction structuring; Capital Markets Advisory, including equity capital markets, restructuring, debt advisory, private placement advisory, market risk management and hedging, private capital advisory, and private funds; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients. The Investment Management segment provides wealth management services to high-net-worth individuals, foundations, and endowments; and manages financial assets for institutional investors. The company was formerly known as Evercore Partners Inc. and changed its name to Evercore Inc. in August 2017. Evercore Inc. was founded in 1995 and is headquartered in New York, New York.
Earnings Per Share
As for profitability, Evercore Partners has a trailing twelve months EPS of $6.39.
PE Ratio
Evercore Partners has a trailing twelve months price to earnings ratio of 30.87. Meaning, the purchaser of the share is investing $30.87 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.78%.
2. Halozyme Therapeutics (HALO)
19.8% sales growth and 261.68% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.41.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 18.69. Meaning, the purchaser of the share is investing $18.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 261.68%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1.4% and 36%, respectively.
Previous days news about Halozyme Therapeutics(HALO)
- According to Zacks on Friday, 14 June, "Another stock from the same industry, Halozyme Therapeutics (HALO Quick QuoteHALO – Free Report) , has gained 9.3% over the past month. "
3. First Hawaiian (FHB)
14.9% sales growth and 9.18% return on equity
First Hawaiian, Inc. operates as a bank holding company for First Hawaiian Bank that provides a range of banking services to consumer and commercial customers in the United States. It operates in three segments: Retail Banking, Commercial Banking, and Treasury and Other. The company accepts various deposit products, including checking and savings accounts, and time deposit accounts. It also provides residential and commercial mortgage loans, home equity lines of credit, automobile loans and leases, personal lines of credit, installment loans, and small business loans and leases, commercial lease financing, and auto dealer financing. In addition, the company offers personal installment, credit card, individual investment and financial planning, insurance protection, trust and estate, private banking, retirement planning, treasury, and merchant processing services. As of December 31, 2020, it operated 54 branches in Oahu, Maui, Hawaii, Kauai, Lanai, Guam, and Saipan. The company was formerly known as BancWest Corporation and changed its name to First Hawaiian, Inc. in April 2016. The company was founded in 1858 and is headquartered in Honolulu, Hawaii. First Hawaiian, Inc. is a subsidiary of BancWest Corporation.
Earnings Per Share
As for profitability, First Hawaiian has a trailing twelve months EPS of $1.74.
PE Ratio
First Hawaiian has a trailing twelve months price to earnings ratio of 11.47. Meaning, the purchaser of the share is investing $11.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.18%.
Yearly Top and Bottom Value
First Hawaiian’s stock is valued at $19.95 at 16:22 EST, way below its 52-week high of $23.22 and way above its 52-week low of $17.18.
4. Curtiss (CW)
10.7% sales growth and 16.88% return on equity
Curtiss-Wright Corporation, together with its subsidiaries, designs, manufactures, and overhauls precision components, and engineered products and services primarily to the aerospace, defense, general industrial, and power generation markets worldwide. The company operates through three segments: Commercial/Industrial, Defense, and Power. The Commercial/Industrial segment offers industrial vehicle products, such as electronic throttle control devices, joysticks, and transmission shifters; sensors, controls and electro-mechanical actuation components used in commercial aircrafts; valves for use in the industrial markets; and surface technology services, including shot peening, laser peening, coatings, and advanced testing. The Defense segment provides commercial off-the-shelf embedded computing board-level modules, data acquisition and flight test instrumentation equipment, integrated subsystems, instrumentation and control systems, turret aiming and stabilization products, and weapons handling systems; avionics and electronics; and aircraft data management solutions to the commercial aerospace market. The Power segment offers hardware, pumps, pump seals, control rod drive mechanisms, valves, fastening systems, specialized containment doors, airlock hatches, spent fuel management products, and fluid sealing products for nuclear power plants and nuclear equipment manufacturers; and naval propulsion and auxiliary equipment, including coolant pumps, power-dense compact motors, generators, steam turbines, valves, and secondary propulsion systems, as well as ship repair and maintenance services primarily to the U.S. navy. Curtiss-Wright Corporation was founded in 1929 and is headquartered in Davidson, North Carolina.Curtiss-Wright Corporation, together with its subsidiaries, designs, manufactures, and overhauls precision components, and engineered products and services primarily to the aerospace, defense, general industrial, and power generation markets worldwide. The company operates through three segments: Commercial/Industrial, Defense, and Power. The Commercial/Industrial segment offers industrial vehicle products, such as electronic throttle control devices, joysticks, and transmission shifters; sensors, controls and electro-mechanical actuation components used in commercial aircrafts; valves for use in the industrial markets; and surface technology services, including shot peening, laser peening, coatings, and advanced testing. The Defense segment provides commercial off-the-shelf embedded computing board-level modules, data acquisition and flight test instrumentation equipment, integrated subsystems, instrumentation and control systems, turret aiming and stabilization products, and weapons handling systems; avionics and electronics; and aircraft data management solutions to the commercial aerospace market. The Power segment offers hardware, pumps, pump seals, control rod drive mechanisms, valves, fastening systems, specialized containment doors, airlock hatches, spent fuel management products, and fluid sealing products for nuclear power plants and nuclear equipment manufacturers; and naval propulsion and auxiliary equipment, including coolant pumps, power-dense compact motors, generators, steam turbines, valves, and secondary propulsion systems, as well as ship repair and maintenance services primarily to the U.S. navy. Curtiss-Wright Corporation was founded in 1929 and is headquartered in Davidson, North Carolina.
Earnings Per Share
As for profitability, Curtiss has a trailing twelve months EPS of $9.71.
PE Ratio
Curtiss has a trailing twelve months price to earnings ratio of 27.42. Meaning, the purchaser of the share is investing $27.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.88%.
Sales Growth
Curtiss’s sales growth is 4.4% for the ongoing quarter and 10.7% for the next.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 17, 2024, the estimated forward annual dividend rate is 0.84 and the estimated forward annual dividend yield is 0.31%.
Yearly Top and Bottom Value
Curtiss’s stock is valued at $266.22 at 16:22 EST, below its 52-week high of $286.65 and way higher than its 52-week low of $171.30.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13%, now sitting on 2.93B for the twelve trailing months.
5. Saia (SAIA)
7.4% sales growth and 20.08% return on equity
Saia, Inc., through its subsidiaries, operates as a transportation company in North America. The company provides less-than-truckload services for shipments between 400 and 10,000 pounds; and other value-added services, including non-asset truckload, expedited, and logistics services. As of December 31, 2021, it operated 176 owned and leased facilities; and owned approximately 5,600 tractors and 19,300 trailers. The company was formerly known as SCS Transportation, Inc. and changed its name to Saia, Inc. in July 2006. Saia, Inc. was founded in 1924 and is headquartered in Johns Creek, Georgia.
Earnings Per Share
As for profitability, Saia has a trailing twelve months EPS of $13.81.
PE Ratio
Saia has a trailing twelve months price to earnings ratio of 32.25. Meaning, the purchaser of the share is investing $32.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.08%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 13.5% and 12.5%, respectively.
6. Canadian National Railway Company (CNI)
7% sales growth and 27.06% return on equity
Canadian National Railway Company, together with its subsidiaries, engages in the rail, intermodal, trucking, and marine transportation and logistics business in Canada and the United States. The company provides rail services, which include equipment, custom brokerage services, transloading and distribution, business development and real estate, and private car storage services; and intermodal services, such as temperature controlled cargo, port partnerships, and logistics parks. It offers trucking services, such as door-to-door services, import and export dray, interline services, and specialized services, comprising flatbed trucks, on-deck mobile transport trays, expedited cargo, and permit/overweight services; and supply chain services. It serves automotive, coal, fertilizers, temperature controlled cargo, forest products, dimensional, grain, metal and minerals, petroleum and chemicals, consumer goods, and third party logistics applications. The company operates a rail network of approximately 20,000 route-miles of track and shipping spanning. Canadian National Railway Company was incorporated in 1919 and is headquartered in Montreal, Canada.
Earnings Per Share
As for profitability, Canadian National Railway Company has a trailing twelve months EPS of $6.29.
PE Ratio
Canadian National Railway Company has a trailing twelve months price to earnings ratio of 20.42. Meaning, the purchaser of the share is investing $20.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.06%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 1.5%, now sitting on 16.76B for the twelve trailing months.
Sales Growth
Canadian National Railway Company’s sales growth is 3.1% for the current quarter and 7% for the next.
Previous days news about Canadian National Railway Company(CNI)
- According to Zacks on Friday, 14 June, "Despite the challenges surrounding the industry,some railroad companies like Union Pacific Corporation (UNP Quick QuoteUNP – Free Report) , Canadian National Railway Company (CNI Quick QuoteCNI – Free Report) and Norfolk Southern Corporation (NSC Quick QuoteNSC – Free Report) have consistently announced dividend hikes, thus highlighting their pro-shareholder stance.", "Canadian National Railway Company dividend-yield-ttm | Canadian National Railway Company Quote"
7. Merit Medical Systems (MMSI)
6.7% sales growth and 8.45% return on equity
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
Earnings Per Share
As for profitability, Merit Medical Systems has a trailing twelve months EPS of $1.74.
PE Ratio
Merit Medical Systems has a trailing twelve months price to earnings ratio of 47.58. Meaning, the purchaser of the share is investing $47.58 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.45%.
Sales Growth
Merit Medical Systems’s sales growth is 7.8% for the ongoing quarter and 6.7% for the next.
